Dr Sonya Miller Featured in PharmaVoice
Sonya Miller follows the science. In 2017, she followed it so completely and with such focus into a crowded conference room that she accidentally sat next to the CEO of TauRx Pharmaceuticals and talked herself into a job.
Our Head of Medical Affairs and Medical Oversight Lead, Dr Sonya Miller, recently spoke with PharmaVoice to discuss her route into TauRx, the importance of optimism in the industry, and the impact tau science is having on Alzheimer’s disease research.
“It’s one of the last great frontiers in medicine - you can’t help but want to keep that optimism to enhance understanding and increase the ability to do something about it.”
Recent News
GT Diagnostics announces release of self-administered assessment tool aiding diagnosis of dementia, HiPAL Pro.
Sep 05, 2023
#AAIC23 may have come to a close, but we left Amsterdam with key insights that will drive our work this year.
Jul 21, 2023
TauRx’s hydromethylthionine mesylate (HMTM) demonstrates significant reduction in neurodegeneration in Alzheimer’s Disease (AD)
Jul 16, 2023
As sponsors of the Alzheimer’s Association International Conference® (AAIC®) in Amsterdam 16 – 20 July, together with joint venture company GT Diagnostics, we will be presenting our latest research in neurodegenerative conditions.
Jul 14, 2023